Raymond James Financial Lowers Abbott Laboratories (NYSE:ABT) Price Target to $115.00

Abbott Laboratories (NYSE:ABT) had its target price dropped by Raymond James Financial from $130.00 to $115.00 in a research note issued on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the healthcare product maker’s stock. Raymond James Financial’s price objective would suggest a potential upside of 18.69% from the stock’s previous close.

ABT has been the topic of several other research reports. Bank of America cut their price target on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a report on Friday. Evercore lowered their target price on Abbott Laboratories from $138.00 to $134.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Benchmark cut their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday. Royal Bank Of Canada reduced their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Piper Sandler lowered their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $121.00.

Abbott Laboratories Trading Up 1.5%

ABT opened at $96.89 on Friday. The company has a fifty day moving average price of $107.89 and a two-hundred day moving average price of $118.65. Abbott Laboratories has a 1-year low of $93.92 and a 1-year high of $139.06. The company has a market cap of $168.75 billion, a P/E ratio of 27.14, a price-to-earnings-growth ratio of 1.57 and a beta of 0.79. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Elizabeth C. Cushman sold 263 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the sale, the executive vice president directly owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. This represents a 0.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,055 shares of company stock worth $353,097 in the last three months. 0.46% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Abbott Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABT. Brighton Jones LLC grew its stake in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC raised its stake in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the period. United Bank boosted its holdings in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC grew its position in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after buying an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board increased its holdings in Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after buying an additional 292,547 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Preliminary settlement reached in six shareholder derivative suits tied to Abbott’s U.S. infant‑formula business, reducing litigation overhang for investors. Read More.
• Positive Sentiment: New data on Cancerguard MCED (multi‑cancer early detection) presented at AACR 2026 — important for Abbott’s growth thesis since the Exact Sciences deal expanded its oncology diagnostics exposure. Continued clinical progress supports longer‑term revenue upside. Read More.
• Positive Sentiment: Insiders added roughly $3.1M of stock, and a number of analysts still see upside — some calling the post‑acquisition pullback a buying opportunity given valuation and Abbott’s dividend track record. Read More. Read More.
• Neutral Sentiment: Q1 results: adjusted EPS $1.15 (vs. $1.14 est.) and revenue $11.16B (vs. $10.99B); company set FY 2026 adjusted EPS guidance to $5.38–$5.58 and Q2 guide to $1.25–$1.31, explicitly including ~$0.20 of dilution from the Exact Sciences acquisition. Investors are parsing beat vs. the guidance change. Read More.
• Neutral Sentiment: Earnings call transcript and analyst commentary emphasize medical‑device strength offset by Diagnostics/Nutrition softness and acquisition-related margin pressure — useful for active traders but mixed for near‑term stock direction. Read More.
• Negative Sentiment: Market reaction: shares fell after the print because Abbott trimmed guidance and flagged Nutrition weakness and margin compression; coverage shows the takeover (≈$21–23B) is dilutive near term. Read More.
• Negative Sentiment: Many brokers lowered price targets and some cut forecasts following Q1/guidance — several firms kept positive ratings but reduced targets (examples include RBC, Jefferies, Raymond James, Citi and others), amplifying short‑term selling pressure. Read More.
• Negative Sentiment: Analyst notes and headlines highlighted the EPS guidance cut and Nutrition slump as primary reasons for the earlier drop — these remain catalysts to watch for the next quarter. Read More.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.